Medtronic has reported late-breaking data from the randomised Evolut Low Risk Trial’s five-year outcomes of the Evolut ...

Patients with aortic stenosis were excluded from earlier trials of the SGLT2 inhibitor, but new data confirm they too can ...

Aortic valve stenosis' is an often-overlooked condition and a growing health concern in ageing societies such as Thailand. With an increasing elderly population and a rise in age-related valve ...

Olive Hospital has achieved a major breakthrough in the field of Interventional Cardiology by successfully completing its ...

A new method of alerting clinical care providers holds promise for increasing treatment and improving survival for patients ...

Edwards Lifesciences (NYSE: EW) today announced new scientific evidence presented and published during the American College of Cardiology’s (ACC) Annual Scientific Session & Expo, addressing the ...

Here are the biggest stories out of ACC 2025: Five-year data from the Medtronic Evolut Low Risk Trial confirmed that its ...

Patients with severe aortic stenosis at low surgical risk who underwent supra-annular, self-expanding Evolut transcatheter ...

With the aging of the population, aortic stenosis affects a growing number of patients, with a prevalence of 12.4% among persons who are at least 75 years of age, among whom 3.4% have severe ...

Medtronic says its Evolut TAVR shows strong valve performance and durable outcomes at 5 years in low-risk aortic stenosis ...

Patients who underwent transcatheter aortic valve replacement (TAVR) with a valve designed to treat aortic regurgitation had ...

A device designed to remove embolic material—fragments of tissue that can be released into the bloodstream during transcatheter aortic valve replacement (TAVR)—did not result in a reduction in the ...